header logo image


Page 11234..10..»

Archive for the ‘Opthalmology’ Category

Ophthalmologists Near Me in Hollywood, FL | Healthgrades

Friday, February 2nd, 2024

Anoptometristis a healthcare provider who specializes in routine and preventive eye and vision care. Optometrists diagnose vision abnormalities and prescribe eyeglasses and contacts. They detect and treat cataracts, glaucoma, and eye infections. Optometrists also screen for conditions that affect the eyes and vision, includinghigh blood pressureand diabetes.

An optometrist typically:

Evaluates a patients medical and vision history

Educates the patient about eye and vision disease prevention and health

Performs a comprehensive eye and vision exam and evaluates blood pressure

Performs and interprets specialized eye tests

Diagnoses and often treats acute and chronic eye diseases and conditions that affect vision, including eye injuries, vision problems, cataracts, and glaucoma

Screens for conditions that increase the risk of eye and vision conditions including diabetes and high blood pressure

Prescribes eye glasses, contacts, and certain medications

Refers patients to an ophthalmologist for serious eye problems and most eye surgeries

Performs laser or glaucoma surgeries in some cases

Provides eye and vision care before and after eye surgery

An optometrist may also be known by the following names:eye doctor, vision care specialist, and Doctor of Optometry (OD).

Read the rest here:
Ophthalmologists Near Me in Hollywood, FL | Healthgrades

Read More...

What Is an Ophthalmologist? – American Academy of Ophthalmology

Wednesday, January 17th, 2024

Country

AfghanistanAland IslandsAlbaniaAlgeriaAll CountriesAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua And BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, St. Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCte d'IvoireCroatia (Hrvatska)CubaCuracaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEnglandEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly See (Vatican City)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKosovoKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacauMacedonia, Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States ofMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern IrelandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRunionRomaniaRussian FederationRwandaSaint BarthelemySaint Kitts And NevisSaint LuciaSaint MartinSamoaSan MarinoSao Tome And PrincipeSaudi ArabiaScotlandSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth GeorgiaSouth SudanSpainSri LankaSt Vincent And GrenadinesSt. HelenaSt. Pierre And MiquelonSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad And TobagoTunisiaTurkeyTurkmenistanTurks And Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands (British)Virgin Islands (U.S.)WalesWallis And Futuna IslandsWestern SaharaYemenZambiaZimbabwe

See the article here:
What Is an Ophthalmologist? - American Academy of Ophthalmology

Read More...

Eye Exam and Vision Testing Basics – American Academy of Ophthalmology

Saturday, November 18th, 2023

Getting an eye exam is an important part of staying healthy. But do you know when you and your family members should get eye exams?Do you know whata complete eye exam should cover?

Get the right exam at the right time and ensure your vision lasts a lifetime.

From birth through the teenage years, children's eyes are growing and changing quickly. The American Academy of Ophthalmology and the American Association for Pediatric Ophthalmology and Strabismus have developed specific childhood eye screening guidelines. Follow these guidelines to get your child screened at the right times. These screenings help identify when your child might need a complete eye exam.

If your eyes are healthy and vision is good, you should have a complete exam by your ophthalmologist once in your 20s and twice in your 30s.

There are some exceptions:

The American Academy of Ophthalmology recommends that adults get a complete eye examination at age 40. This is when early signs of disease or changes in vision may appear. It is important to find eye diseases early. Early treatment can help preserve your vision.

Some adults shouldn't wait until they are 40 to have a complete eye exam. See an ophthalmologist now if you have an eye disease or risk factors such as:

After an exam, your ophthalmologist can tell you how often you should have your eyes checked in the future. It's important to follow the schedule your ophthalmologist gives you, especially as you age. Your risk for eye disease increases as you get older.

If you are 65 or older, make sure you have your eyes checked every year or two. Your ophthalmologist will check for signs of age-related eye diseases such as:

Remember, always follow the schedule your ophthalmologist recommends for future eye exams.

A comprehensive eye exam is simple and comfortable. It shouldn't take more than 45 to 90 minutes. Your doctor may have a staff member do portions of this exam. Here is what the exam should include:

Your doctor will ask you about your vision and your general health.They will ask about:

This is the part of an eye exam people are most familiar with. You will read aneye chart to determine how well you see at various distances. You cover one eye while the other is being tested. This exam will determine whether you have20/20 vision or not.

Your doctor will ask you tolook at an eye chart through a device called a phoroptor. The phoroptor contains different lenses. It will help determine the best eyeglass or contact lens prescription for you.

Your doctor may check how yourpupils respond to light by shining a bright beam of light into your eye. Pupils usually respond by getting smaller. If your pupils widen or don't respond, this may reveal an underlying problem.

Loss of side vision (peripheral vision)may be a symptom of glaucoma. This test can find eye problems you aren't aware of because you can lose side vision without noticing.

A test called ocular motility evaluates the movement of your eyes. Your ophthalmologistlooks to see ifyour eyes are aligned.They also check that youreye muscles are working properly.

Eye pressure testing, called tonometry, measures the pressure within your eye (intraocular eye pressure, or IOP). Elevated IOP isonesign of glaucoma. The test may involve a quick puff of air onto the eye or gently applying a pressure-sensitive tip near or against your eye. Your ophthalmologist may use numbingeye drops for this test for your comfort.

Your ophthalmologist uses a slit-lamp microscope to light up the front part of the eye. This includes the eyelids, cornea,iris and lens. This test checks for cataracts or any scars or scratches on your cornea.

Your ophthalmologist will putdilating eye drops in your eye to dilate, or widen, your pupil. This will allowthemto examine yourretina andoptic nerve for signs of damage from disease. Your eyes might besensitive to light for a few hours after dilation.

Your ophthalmologist may suggest other tests to further examine your eye. This can include specialized imaging techniques such as:

These tests help your ophthalmologist detect problems in the back of the eye, on the eye's surface or inside the eye to diagnose diseases early.

Each part of the comprehensive eye exam provides important information about the health of your eyes. Make sure that you get a completeeye exam as part of yourcare for your overall health.

Visit link:
Eye Exam and Vision Testing Basics - American Academy of Ophthalmology

Read More...

Oliver Douglas Schein, M.D., M.P.H. – Johns Hopkins Medicine

Monday, October 16th, 2023

Oliver Schein, M.D., M.P.H., is the Burton E. Grossman Professor of Ophthalmology at the Wilmer Eye Institute and carries a joint appointment in the Department of Epidemiology at the Johns Hopkins University Bloomberg School of Public Health. Dr. Schein's clinical expertise is in medical and surgical conditions of the anterior segment of the eye including cataract and complications of cataract surgery, corneal scarring and corneal surgery. He is a past author of the American Academy of Ophthalmology's "Preferred Practice Pattern" on Cataract. Research activities are directed toward the epidemiology of major ocular diseases, ophthalmic technology assessment and outcomes research in ophthalmology.

Dr. Schein received his M.D. and M.P.H. degrees from Johns Hopkins University and completed his ophthalmology residency and cornea and external eye disease fellowship at Harvard University's Massachusetts Eye and Ear Infirmary. He joined the Wilmer faculty in 1988.

Go here to see the original:
Oliver Douglas Schein, M.D., M.P.H. - Johns Hopkins Medicine

Read More...

Michael Xavier Repka, M.D., M.B.A. – Johns Hopkins Medicine

Monday, October 16th, 2023

Michael X. Repka, M.D., M.B.A., is the David L. Guyton, M.D., and Feduniak Family Professor of Ophthalmology at the Wilmer Eye Institute.He specializes in pediatric ophthalmology, strabismus, retinopathy of prematurity and pediatric neuro-ophthalmology. His clinical practice includes an interest in the management of strabismus and amblyopia. In these areas, he has a special interest in using alternatives to patching for the management of amblyopia and using strabismus surgery, botulinum toxin and adjustable sutures to treat strabismus. He also performs cataract surgery and intraocular lens implantation on children with cataracts and has a special interest in pediatric neuro-ophthalmology involving normal and abnormal visual development and the effect of injury and tumor on the visual system of the child.

Dr. Repka received his M.D. degree from Thomas Jefferson University and completed his ophthalmology residency at Wills Eye Hospital. He completed fellowships in neuro-ophthalmology andpediatric ophthalmologyat the Wilmer Eye Institute and joined the faculty in 1985. In addition to his clinical responsibilities, Dr. Repka is the vice chair for clinical practice at Wilmer.

Dr. Repka is the past chairman of the Pediatric Eye Disease Investigator Group and past president of the Maryland Society of Eye Physicians and Surgeons. He is medical director of Government Affairs of the American Academy of Ophthalmology.

See the rest here:
Michael Xavier Repka, M.D., M.B.A. - Johns Hopkins Medicine

Read More...

Esen Karamursel Akpek, M.D. – Johns Hopkins Medicine

Monday, October 16th, 2023

Esen K. Akpek, M.D., is an internationally renowned leader in the fields of corneal transplantation and surface reconstruction. She is an expert in all forms of cataract surgeries, as well as combined cataract and cornea surgery procedures. She currently sees patients in the Wilmer Eye Institute's locations at The Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center.

The Bendann Professor of Ophthalmology at the Johns Hopkins University School of Medicine, Dr. Akpek has been on the surgical faculty of the Wilmer Eye Institute since 1999.

Dr. Akpeks clinical and research expertise centers on the inflammatory diseases of the ocular surface. She currently serves as the director of the Ocular Surface Disease and Dry Eye Clinic at Wilmer and the associate director of the Jerome L. Greene Sjgrens Center at Johns Hopkins Bayview Medical Center. She has been involved in major dry eye initiatives including TFOS DEWS II in 2017 and the International Meibomian Gland Dysfunction Workshop in 2011. She is a member of the Clinical Trials Consortium-Sjgrens Syndrome Foundation, OMERACT (Outcomes Measures in Rheumatology) initiative for Sjgrens syndrome, member of the Medical & Scientific Advisory Board of the Tear Film and Ocular Surface Society (TFOS). She has led many clinical trials funded by industry as well as the Department of Defense and the National Eye Institute evaluating advanced treatments and diagnostic options for patients with dry eye disease.

Dr. Akpek is the former director of the fellowship program in cornea and external disease and former co-director of Ophthalmology Clerkship at Wilmer and has trained numerous ophthalmologists who have become leaders in the field. She has lectured extensively nationally and abroad, is involved in the organization of multiple online and in-person educational activities including Sonoma Eye, International Ocular Inflammation Society, the Foster Ocular Inflammation Society, and Wilmer Dry Eye Meeting. She has published over 180 articles in peer-reviewed journals, many book chapters, editorials, and review articles. Currently, Dr. Akpek is the president of the Foster Ocular Immunology Society. She serves on the editorial board of 11 scientific journals.

Her previous appointments include serving as member of the Board of Directors for the Cornea Society, medical director of KeraLink International and CorneaGen. She currently serves on the Preferred Practice Patterns Committee for the American Academy of Ophthalmology, where she received its Senior Honor Award. She also received many other awards including the Cora Verhagen Immunology Prize, and a scholarship from the Research to Prevent Blindness.

Dr. Akpek received her medical degree from Hacettepe University in Ankara, Turkey. Following her internship and residency training in Ankara Numune Hospital, she completed a subspecialty training in Ocular Immunology and Uveitis at the Massachusetts Eye and Ear Infirmary, Harvard University Medical School. She then completed a second fellowship program in cornea, cataract and external diseases at the Wilmer Eye Institute.

See the original post here:
Esen Karamursel Akpek, M.D. - Johns Hopkins Medicine

Read More...

Thomas Vincent Johnson III, M.D., Ph.D. – Johns Hopkins Medicine

Monday, October 16th, 2023

Lab

Lab Website: Johnson Laboratory

View all on PubMed

Johnson TV, Martin KR. Development and characterization of an adult retinal explant organotypic tissue culture system as an in vitro intraocular stem cell transplantation model. Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3503-12. doi: 10.1167/iovs.07-1601. Epub 2008 Apr 11. PubMed PMID: 18408186.

Johnson TV, Oglesby EN, Steinhart MR, Cone-Kimball E, Jefferys J, Quigley HA. Time-Lapse Retinal Ganglion Cell Dendritic Field Degeneration Imaged in Organotypic Retinal Explant Culture. Invest Ophthalmol Vis Sci. 2016 Jan 1;57(1):253-64. doi: 10.1167/iovs.15-17769. PubMed PMID: 26811145; PubMed Central PMCID: PMC4736988.

Johnson TV, DeKorver NW, Levasseur VA, Osborne A, Tassoni A, Lorber B, Heller JP, Villasmil R, Bull ND, Martin KR, Tomarev SI. Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain. 2014 Feb;137(Pt 2):503-19. doi: 10.1093/brain/awt292. Epub 2013 Oct 30. PubMed PMID: 24176979; PubMed Central PMCID: PMC3914467.

Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2051-9. doi: 10.1167/iovs.09-4509. Epub 2009 Nov 20. PubMed PMID: 19933193; PubMed Central PMCID: PMC2868400.

Johnson TV, Bull ND, Martin KR. Identification of barriers to retinal engraftment of transplanted stem cells.Invest Ophthalmol Vis Sci. 2010 Feb;51(2):960-70. doi: 10.1167/iovs.09-3884. Epub 2009 Oct 22. PubMed PMID: 19850833; PubMed Central PMCID: PMC2868445.

Read the original post:
Thomas Vincent Johnson III, M.D., Ph.D. - Johns Hopkins Medicine

Read More...

Megan Elizabeth Collins, M.D., M.P.H. – Johns Hopkins Medicine

Monday, October 16th, 2023

Megan Collins, M.D., the Allan and Claire Jensen Professor of Ophthalmology, is a pediatric ophthalmologist who provides comprehensive clinical and surgical care to pediatric patients and adults with strabismus in Baltimore, Maryland. An assistant professor of ophthalmology, Dr. Collins specializes in the diagnosis and treatment of retinopathy of prematurity, pediatric craniofacial malformations and adult strabismus. She is also an associate faculty member at the Johns Hopkins Berman Institute of Bioethics.

In addition to her clinical practice, she directs the Wilmer pediatric ophthalmology fellowship program and is course director for the Wilmer residency ethics and professionalism curriculum.

Dr. Collins received her medical degree from the University of Chicago, where she also completed a fellowship in clinical medical ethics at the MacLean Center for Clinical Ethics. After an internship in internal medicine at the University of Maryland, she returned to the University of Chicago for her residency in ophthalmology, followed by a fellowship in pediatric ophthalmology and adult strabismus at the University of Torontos Hospital for Sick Children. She later received her Masters in Public Health from the Johns Hopkins University Bloomberg School of Public Health.

Read more:
Megan Elizabeth Collins, M.D., M.P.H. - Johns Hopkins Medicine

Read More...

Tin Yan Alvin Liu, M.D. – Johns Hopkins Medicine

Monday, October 16th, 2023

T. Y. Alvin Liu, M.D. is an assistant professor of ophthalmology and the founding director of the Wilmer Precision Ophthalmology Center of Excellence. He is originally from Hong Kong, and speaks fluent Cantonese and Mandarin. He attended Phillips Exeter Academy in Exeter, New Hampshire, and graduated from Cornell University with a dual major in biology and economics. He received his M.D. from Columbia University in 2012, and completed his residency (2016) and fellowship (surgical and medical retina- 2018) at Johns Hopkins.

He is subspecialty-trained in the medical and surgical treatment of vitreoretinal diseases, including age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vascular occlusion, retinal detachment, vitreous hemorrhage, epiretinal membrane and macular hole.

Dr. Liu's research interests center on the application of artificial intelligence in the screening, diagnosis, prognostication and treatment of ophthalmic diseases, with a specific focus on vitreoretinal diseases such as age-related macular degeneration and diabetic retinopathy.

In addition, he is involved in research on the pathogenesis of and treatment for pathologic myopia and the management of severe ocular trauma.

See the article here:
Tin Yan Alvin Liu, M.D. - Johns Hopkins Medicine

Read More...

What is an Ophthalmologist? Definition & Types – Cleveland Clinic

Monday, May 1st, 2023

OverviewWhat is an ophthalmologist vs an optometrist?

An ophthalmologist is an eye care specialist. Unlike optometrists and opticians, ophthalmologists are doctors of medicine (MD) or doctors of osteopathy (DO) with specific training and experience in diagnosing and treating eye and vision conditions.

An ophthalmologist is qualified to deliver total eye care, meaning vision services, eye examinations, medical and surgical eye care, and diagnosis and treatment of disease and visual complications that are caused by other conditions, like diabetes.

An ophthalmologist has completed four years of pre-medical undergraduate education, four years of medical school, one year of internship, and three or more years of specialized medical and surgical training in eye care. As a qualified specialist, an ophthalmologist is licensed by a state regulatory board to diagnose, treat, and manage conditions affecting the eye and visual system.

An ophthalmologist can take care of all your eye care needs, but you should consider working with an ophthalmologist any time you have a serious eye problem that will require surgery or specialized treatment.

Ophthalmologists perform surgery for the following eye problems:

Here are some examples of conditions when you might seek treatment from an ophthalmologist:

Regular eye screening is another thing you can do to protect your and your familys good health. Your eye health can change over time, so its a good idea to plan for regular eye examinations.

Most routine eye examinations start with questions about your eyes:

Next, your ophthalmologist will ask about your history of wearing eyeglasses or using contacts. They might also ask about your overall health and your family medical history, including any specific eye problems.

Your ophthalmologist will perform several tests to learn more about your eye health:

You might see your ophthalmologist as part of a regular checkup or for a specific eye problem. Either way, youll want to know whats happening with your eye health. Here are a few questions for you to consider:

A note from Cleveland Clinic

Protecting your eye health should be one of your personal health priorities. Few things in life are as precious as the ability to see clearly. Fortunately, there are many ways to treat common eye problems. Make your eye health a priority by having eye examinations as recommended by your ophthalmologist and seeking help anytime you notice changes in your vision.

Read more:
What is an Ophthalmologist? Definition & Types - Cleveland Clinic

Read More...

Optometrist vs. Ophthalmologist: Choosing Your Eye Care Provider

Friday, April 7th, 2023

If youve ever had to search for an eye care doctor, youre likely aware that there are several different types of eye specialists. Optometrists, ophthalmologists, and opticians are all professionals who specialize in eye care.

An optometrist is an eye doctor that can examine, diagnose, and treat your eyes. An ophthalmologist is a medical doctor who can perform medical and surgical interventions for eye conditions. An optician is a professional who can help fit eyeglasses, contact lenses, and other vision-correcting devices.

In this article, we will explore the education requirements, salary, scope of practice, and services that optometrists, ophthalmologists, and opticians provide. We will also discuss how to choose the best eye-care professional for your needs.

An optometrist is the primary health care provider for routine eye care.

An optometry program is a postgraduate program that takes roughly 4 years to complete, depending on the school and curriculum. The program curriculum includes:

Optometry program coursework also includes full-time clinical training as a resident during the final 1 to 2 years of the program.

In 2018, the median salary for optometrists was $111,790, according to the Bureau of Labor Statistics.

You can visit an optometrist for your yearly eye exam, to refill an eyeglass or contact prescription, or even to receive medication and treatment for certain eye conditions. Unlike an ophthalmologist, an optometrist is not a surgical specialist and cannot treat more serious eye conditions.

Optometrists provide the following services::

Optometrists can prescribe controlled medications for eye conditions. Depending on the state legislation, some optometrists can also perform minor surgeries. These surgical procedures may include foreign body removal, laser eye surgery, and certain additional surgical interventions.

An ophthalmologist is a medical doctor who specializes in surgical eye procedures.

All ophthalmologists must complete a full medical program before they can begin a residency program in ophthalmology. An ophthalmology residency program takes an additional 4 to 7 years to complete, depending on the school and curriculum. The residency program expands on:

Ophthalmology residency training also includes the hands-on care of patients, which involves performing surgical procedures under supervision. The residency program generally follows a one year internship.

In 2018, the average salary for ophthalmologists was $290,777 according to Salary.com.

You can visit an ophthalmologist for the same care as an optometrist, such as a routine eye exam or prescription refill. However, an ophthalmologist can also perform eye surgery for various diseases and conditions, including cataracts, glaucoma, and strabismus surgery, plus more.

Ophthalmologists provide the following services:

Ophthalmologists receive 12 or more years of training in order to be able to perform in-depth surgical procedures for diseases of the eyes. Given that this is their specialty, almost all ophthalmologists will focus on this as their primary scope of care.

Depending on the scope of practice within the state, both optometrists and ophthalmologists can perform eye surgery. However, optometrists are limited in the surgeries they can perform while ophthalmologists can perform any and all surgical procedures they are trained for.

An optician is a customer service representative who works in a vision care store or optometrists office.

Optician training is much more informal than optometry or ophthalmology training. An optician does not necessarily need to hold a formal degree. An optician can become certified by completing a 1- to 2-year program, such as an associates program in ophthalmic dispensing.

An optician may also become certified through an in-house apprenticeship under an ophthalmologist or optometrist.

In 2018, the median salary for opticians was $37,010 according to the Bureau of Labor Statistics.

Opticians perform customer service duties at your optometrists office or local vision care center. You can visit an optician for routine care, adjustment, and refilling of prescription eyeglasses and contact lenses.

Opticians can also answer general eye care questions, but they cannot examine, diagnose or treat diseases of the eye.

Opticians provide the following services:

Unlike optometrists and ophthalmologists, opticians are not allowed to perform any eye exams or diagnose or treat any eye conditions.

How do you know which provider you should choose for your eye care? Choosing an optometrist, ophthalmologist, or optician will depend on the service you need.

Optometrists, ophthalmologists, and opticians are all eye care professionals who differ in their education, specialty, and scope of practice.

Optometrists are basic eye care specialists who can examine, diagnose, and medically treat eye conditions. Ophthalmologists are a type of medical doctor who specialize in surgical procedures of the eye. Opticians are customer service specialists who work in vision care centers and optometry offices.

Choosing the right eye care professional for you will depend on what services you need. For a comprehensive list of optometrists near you, check out the American Optometric Associations Find a Doctor tool.

Read the original:
Optometrist vs. Ophthalmologist: Choosing Your Eye Care Provider

Read More...

What is ophthalmology? Medical conditions, procedures, and more

Friday, April 7th, 2023

Ophthalmology is the study of medical conditions relating to the eye. Ophthalmologists are doctors who specialize in the medical and surgical treatment of this organ.

A general practice doctor may refer someone to an ophthalmologist if they show symptoms of cataracts, eye infections, optic nerve problems, or other eye conditions.

In this article, we look at what ophthalmologists do, including the types of conditions that they treat, the procedures they perform, and when a person might see this specialist.

An ophthalmologist is a medical doctor who specializes in diagnosing and treating eye-related conditions.

To practice in the United States, ophthalmologists must complete:

Some ophthalmologists undergo a year or two of fellowship training specializing in one of the many subspecialties of ophthalmology, such as:

Subspecialist ophthalmologists have usually completed training that allows them to work on eye conditions that are complex, involve a specific part of the eye, or affect certain groups of people. They also train more extensively than regular ophthalmologists to perform extremely intricate surgeries on delicate parts of the eye.

Ophthalmologists are responsible for the diagnosis, prevention, and treatment of almost all eye conditions and visual issues.

However, subspecialist ophthalmologists tend to treat and monitor certain conditions, such as:

Aside from caring for the eyes and vision, an ophthalmologists medical training may also equip them to notice symptoms of conditions that do not directly relate to the eye. In such cases, they can refer people for the appropriate treatment.

Many ophthalmologists also participate in some form of scientific research focusing on the causes of eye and vision conditions, as well as potential cures.

Most ophthalmologists are trained and certified to perform a wide range of medical and surgical procedures. The procedures that an ophthalmologist regularly carries out depend on several factors, such as the type of practice and specialty in which they work.

Some of the most common everyday procedures that an ophthalmologist will perform include diagnosing and monitoring mild eye and vision conditions. They will also spend time prescribing and fitting glasses and contact lenses to correct vision problems.

Subspecialist ophthalmologists tend to perform a smaller range of procedures on a day-to-day basis, focusing instead on the treatment of one condition or a few related conditions.

Procedures that subspecialists commonly perform include:

Most people see an ophthalmologist because they are experiencing chronic or severe vision symptoms or signs of eye conditions, such as:

A person may need emergency care from an ophthalmologist if their symptoms include:

A person may also receive a referral to an ophthalmologist if they have conditions or factors that can increase the risk of eye conditions, such as:

A family doctor, pediatrician, emergency room doctor, or optometrist usually refers a person to an ophthalmologist.

The American Academy of Ophthalmology recommend that people have a full medical eye exam by the age of 40 years so that an ophthalmologist can create a baseline profile of their eye health.

Having an eye health baseline is important because it makes it easier for doctors to spot or track eye or vision changes, which are often subtle and difficult to detect. Even healthy people can suddenly experience severe eye conditions.

Unlike ophthalmologists, optometrists and opticians are not medical doctors. However, members of all three distinct professions can, and frequently do, work in the same office or practice.

Optometrists are healthcare professionals who provide primary vision care. Optometrists hold a Doctor of Optometry (OD) degree, which requires the completion of 34 years of college and then 4 years of optometry school.

While the procedures that they perform vary between states and individual practices or clinics, most optometrists:

Opticians are a type of healthcare technician. They are specially trained to help design, confirm, select, or fit corrective vision devices, including contact lenses and eyeglass lenses and frames. Opticians cannot diagnose or treat conditions and must follow the prescription and guidance of optometrists and ophthalmologists.

The other eye healthcare professionals who frequently work with ophthalmologists and optometrists include:

Ophthalmologists are medical doctors who have undergone specialist training to diagnose and treat conditions involving the eyes and vision. They perform a wide range of medical and vision tests, minor office procedures, and some surgeries.

Some ophthalmologists specialize in a specific branch of ophthalmology that deals with particular procedures, parts of the eye, or groups of people.

A family doctor, pediatrician, or emergency room doctor usually refers a person to an ophthalmologist because of eye or vision problems. They refer people with symptoms and signs of conditions that need treating or monitoring.

Someone might also see an ophthalmologist if they have a higher risk of eye conditions or have health conditions that often lead to vision problems.

According to eye health authorities, most people should have an ophthalmologist perform a complete eye exam before the age of 40 years to establish a baseline profile of their eye health.

Link:
What is ophthalmology? Medical conditions, procedures, and more

Read More...

Ophthalmology Services & Information | UCLA Health

Friday, April 7th, 2023

Aesthetic Center

Experts treat patients who want to enhance their appearance through surgery. For example, treatment might involve eyelid reshaping, fat transfer or liposuction to alter a persons facial features. Patients who want aesthetic surgery receive care from specialists trained in both ophthalmic and plastic surgery.

UCLA Health ophthalmology conductsresearch in public health ophthalmology and provide high-impact, community-based services. For example, our Mobile Eye Clinic improves access to care in underserved communities.

Specialists use a team approach to research blinding diseases. Private donations, including an endowment established by the Ahmanson Foundation, fund this research center, established in 1997.

We provide core support for studies that include patient care. Every clinical trial and study involves vital, behind-the-scenes details that enable us to continue this research. At present, we are conducting almost 80 clinical research studies to help us better understand eye disorders and treatments.

Our ophthalmologists specialize in treating patients with diabetes-related eye conditions. Established more than a decade ago, the center has contributed significantly both to the understanding and the care of eye diseases in people with diabetes.

Specialists provide ultramodern vision correction treatments. We were one of a limited number of study sites in the United States that participated in the Food and Drug Administration (FDA) clinical trial of excimer laser technology. We also were the first site in Los Angeles to use FDA-approved laser treatment to correct myopia (nearsightedness) and astigmatism (imperfect eye curvature).

Our team offers high-quality care and rehabilitation and promotes collaborative research for macular degeneration (an eye disease that causes vision loss). Patients in this program, established in 1994, often have access to new treatments through clinical trials.

For more than 40 years, weve provided eye exams and screenings in neighborhoods where poverty and vision disabilities intersect. This 39-foot-long bus is outfitted with equipment for eye exams and supported by charitable donations. Each year, we provide eye care to more than 20,000 underserved adults and children in Southern California.

We established this center in 1985 to coordinate research, education and patient care of inflammatory eye disorders. Inflammatory diseases include those that cause eye swelling and destroy tissue. We have a long history of participating in clinical and drug therapy trials that advance our understanding of these diseases.

Specialists have renowned expertise in teaching, research and clinical management of tumors. Our program has achieved international recognition for the diagnosis and treatment of ocular melanoma (cancer of the eye).

We serve as a hub for national, long-term studies that investigate eye cancer. We also played an important role in the Collaborative Ocular Melanoma Study, a significant research initiative sponsored by the National Eye Institute.

Experts treat conditions that affect the optic nerve. Your optic nerves carry images from your eyes to your brain so you can see. If you have an optic nerve condition, your treatment might involve the expertise of ophthalmologists, orbital surgeons, neurologists, neuroradiologists or neurosurgeons.

We study and treat orbital (bony eye socket) diseases brought on by trauma, cancer, inflammation or infection. Our multidisciplinary collaboration offers patients a level of knowledge and expertise not found elsewhere in Southern California. We also have an active program in thyroid eye diseases, through which we study eye conditions that also affect your endocrine system.

We address the full spectrum of hereditary eye disorders (disorders you inherit from your parents). We offer diagnosis and treatment, as well as genetic counseling or DNA testing when appropriate.

Specialists in the Vision Genetics Center, established in 1978, collaborate with genetic research groups around the world. Our efforts ensure that patients have access to the most advanced treatments and clinical trials.

Our team provides rehabilitation services to help people with low vision maximize their function and improve their quality of life. We tailor the treatment plan to a patients individual goals and can help anyone who has difficulty with visual tasks, such as reading.

We also conduct research studies and pioneer novel ways to help people with vision loss. For example, we developed a system that uses rehabilitation delivered virtually to increase access to care. The approach involves video conferencing with a doctor. Now, we are part of a national, multicenter trial to evaluate how this new approach can improve reading ability.

Our specialists are experts in diagnosis, treatment and management of all conditions that affect the eyes, including pediatric vision concerns. Common conditions we treat include:

Astigmatism: An imperfect curving of your eye that causes blurry vision.

Blepharitis: Eyelid inflammation that can lead to dry eyes, redness or swelling.

Cataracts: When proteins build up in your eye and cause cloudy or fuzzy vision.

Conjunctivitis (pinkeye): Inflammation or infection in your eye that causes itching, redness and crusting around the eye.

Glaucoma: Conditions that damage your optic nerve (nerve that carries images to your brain), often caused by a buildup of pressure in your eye.

Macular degeneration: Deterioration of your retina (the back part of your eye that interprets and sends images to your brain).

Myopia (nearsightedness): A common vision condition in which you can focus on close objects but not on objects that are far away.

Our goal is to find the best, most effective treatment options for eye conditions. We provide a range of nonsurgical and surgical treatments.

Our specialists care for both routine and complex eye conditions. Nonsurgical treatments we offer include:

Anti-glare glasses: Devices designed to improve vision while reducing eye strain.

Artificial tears: Eyedrops that improve lubrication and moisture on your eyes surface.

Contact lenses: Thin devices placed directly over your eyes surface to improve vision.

Eye drops: Drops that contain saline and medication such as steroids or antihistamines.

Eye patches: A device made of cloth, plastic or an adhesive bandage that covers the eye.

Warm compresses for your eyes: Applying a clean, warm cloth over your eyes to relieve swelling, pain or inflammation.

We offer research-based, advanced surgical treatments for a range of eye conditions. Common surgeries include:

Blepharoplasty: Plastic surgery to change the appearance of your eyelids, often by correcting droopiness.

Corneal transplant: Repairing your cornea (transparent tissue that covers your eye) with donor tissue.

Orbital decompression: Removing fat or bone from behind the eye so that your eye sits back further in its socket.

Photodynamic therapy: Combining light energy with specific drugs to destroy precancerous or cancerous cells.

Pneumatic retinopexy: Injecting your eye with a small air bubble to push the retina in place while your surgeon repairs retinal tears.

Strabismus surgery: Surgically loosening or tightening eye muscles to correct irregular eye alignment (crossed eyes).

Vitrectomy: Removing fluid from the eye to treat problems with the retina or vitreous humor (the gel-like tissue that fills your eyeball).

The specialists on our ophthalmology team have led the way in the research and clinical care of eye conditions. We use the latest techniques and have pioneered advanced treatment options.

Call 310-825-5000 to request an appointment with an eye specialist at UCLA Health.

Original post:
Ophthalmology Services & Information | UCLA Health

Read More...

Punctal Plugs – American Academy of Ophthalmology

Tuesday, December 20th, 2022

Many people suffer from dry eye, when their eyes do not make enoughtears or the right quality of tears.Eye drops are often used to treat dry eye. However, some people find that having punctal plugs inserted into their eyes can help make them more comfortable.

Punctal plugs are tiny devices that are placed in the eyes tear ducts (called puncta). Puncta are the tiny openings that drain tears from your eyes. About the size of a grain of rice, the plug stops fluid from draining from the eye. This helps keep the eyes surface moist and comfortable, relieving itchy, burning and red eyes.

Punctal plugs are also called punctum plugs, lacrimal plugs or occluders. Usually they are inserted in the puncta of the upper or lower eyelids, or in both. Another type of plug is placed in a deeper part of the tear duct (the canaliculus).

These are made of a material (such as collagen) that gradually breaks down and is absorbed by the body. These plugs can last in the eye from a few days to months. Temporary plugs are often used to keep the eye moist after having refractive surgery, such as LASIK. They are also used when you want to try out punctal plugs to see if they help relieve your dry eye.

These are made of a longer-lasting medical plastic (such as silicone or acrylic). These plugs are designed to stay in the eye for years. They can be removed by your ophthalmologist if needed.

Another type of semi-permanent punctal plug is placed in a deeper part of the tear duct called the canaliculus. These plugs cannot be seen at all in the eye.

First your eye doctor will examine your eye to figure out the best type and size plug for your needs.

Your doctor may numb your tear ducts with anesthesia. In some cases, you may not need to have your eyes numbed. You may feel some pressure as the punctal plug is placed in your eyelid.

After the plugs are inserted, you are usually able to return to your normal activities right away.

As with any treatment or procedure, punctal plugs can have possible risks and side effects.

The most common side effect is having a scratchy orirritating feeling in the corner of your eye. Many people find this feeling goes away or they simply get used to it.

Other side effects and risks may include the following:

Most people find punctal plugs do not cause any problems. However, side effects can happen. If you feel any eye pain, scratchiness or if you think you have an eye infection, tell your eye doctor right away. They may choose to remove the plugs.

How the plugs are removed depends on which type you have. To remove silicon plugs, your eye doctor will use forceps to gently pull the plugs from the tear duct. Another way to remove these plugs is by flushing them out with a salt water solution. This method forces the plugs out of the tear ducts into the nose or throat.

Plugs that are deeper in the tear duct (in the canaliculus) are removed with surgery.

If artificial tears or other eye drops have not relieved your dry eye symptoms, talk with your ophthalmologist. They may recommend trying punctal plugs.

Go here to see the original:
Punctal Plugs - American Academy of Ophthalmology

Read More...

Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for…

Sunday, May 8th, 2022

Selection of lead candidate from initial short-list of 6 DMT-analogues

Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types

In vitro safety and biocompatibility testing using drug-loaded medical device demonstrates tolerability at doses anticipated to be within therapeutic range

Results to be leveraged by filing of Provisional Patent detailing a novel approach to treating primary open angle glaucoma

Initiates plans for second stage of R&D with Terasaki Institute for Biomedical Innovation

Toronto, Ontario--(Newsfile Corp. - May 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), has selected its final lead drug candidate from a short list of six N,N-Dimethyltryptamine (DMT) analogue molecules. This decision, based on successful completion of the first phase of the sponsored research agreement, derives from the demonstration of lead candidate superiority as it relates to in vitro potency in two predictive bioassays, a favorable toxicity profile as well as physical, chemical, and metabolic properties necessary to fabricate a proprietary medical device capable of conveniently delivering sub-psychedelic levels of drug to the front of the eye over a sustained period.

With efforts related to discovery and candidate selection now complete, the Company intends to advance its program in primary open angle glaucoma (POAG) by entering into a second sponsored research collaboration with TIBI to undertake 1) mechanism of action studies, 2) optimize medical device drug release characteristics, 3) in vitro host-species justification studies to support, 4) evaluation of drug efficacy in an IND-enabling study of POAG with the goal of providing all necessary support to file an investigative new drug (IND) application with the United States Food and Drug Administration (the "FDA") to conduct clinical studies.

Paul Van Slyke, CSO of PharmaDrug, commented, "We are excited to announce that in collaboration with TIBI, we have successfully completed the studies necessary to elect the Company's lead drug candidate for the treatment of POAG. The next phase of this ongoing collaboration will start shortly and is underlined by the Company's strong commitment to work with outstanding research and development groups from around the world to provide innovative, life changing medications to patients at risk of vision loss as a consequence of insufficiently treated glaucoma."

Story continues

Under the terms of the first sponsored research agreement, PharmaDrug's DMT-analogue research program aimed to elect a drug development lead based on biological potency and toxicity and to use the development lead to engineer a medical device capable of sustained drug delivery to the front of the eye. The Company has now selected its lead candidate and completed fabrication and initial testing of its novel medical device designed to deliver therapeutic quantities of its DMT-analogues to the front of the eye. Specifically, drug-loaded medical device prototypes were suspended in a biological solution meant to mimic the somewhat harsh environment of the eye. Samples, maintained at body temperature were removed at defined periods of time over sixteen days and were quantified to determine concentration and rate of drug release and breakdown. Stability of the lead candidate molecule met necessary criteria set forth by the Company. The biocompatibility of drug-loaded medical device was examined by way of quantifying cell proliferation and live/dead staining on human ciliary muscle cells over time. Concentrations expected to be within the therapeutic range were found to not statistically impact cell viability the drug-loaded medical devices.

Most recently, potency of the lead candidate was evaluated in an in vitro cyclic adenosine 3':5' monophosphate (cAMP) production assay using human, primary trabecular meshwork (TM) cells and ciliary muscle (CM) cells. These cells, richly decorated with serotonin receptor 1a and 2a (5HT-1a, 5HT-2a), play a central role in the maintenance of healthy intraocular pressure. Tryptamine molecules, such as the Company's lead candidate are thought to bind to these receptors and elicit downstream biological outcomes which assist in the active drainage (reduction of pressure) of aqueous humor from the front of the eye to the posterior compartment. The Company's lead candidate demonstrated potent cAMP production following application, a statistically significant superiority compared to other candidate molecules examined (p<0001), and an unexpected bias towards cAMP production in TM cells versus CM cells.

Test article potency was previously evaluated using an in vitro calcium mobilization assay on TM and CM cells. Calcium mobilization is understood to provoke smooth muscle contraction, and specifically in the case of TM and CM cells, is thought to contribute to the maintenance of healthy IOP by channeling aqueous humor away from the front of the eye. The Company's lead candidate was found to activate calcium mobilization, to levels that were comparable or greater than the experimental positive control, ionomycin. The lead candidate was also examined for in vitro toxicity and found to be non-toxic to TM and CM cells at concentrations expected to be used in treatment for various eye diseases. Collectively results from the first phase of the sponsored research agreement will be used to draft an upcoming Provisional Patent application which describes use of tryptamine family members, fabricated into a proprietary medical device, to treat conditions marked by elevated intraocular pressure.

The Need for Improved Medications to Treat Primary Open Angle Glaucoma

Glaucoma is a disorder of the optic nerve that results in irreversible vision loss and is the second leading cause of blindness in the world, according to the World Health Organization. Glaucoma impacts more than 2.7 million people aged 40 or older in the United States and current treatments are known to have poor rates of compliance of up to 80% of patients. The global market for glaucoma was estimated by Market Scope at $4.8 billion in 2019 with the U.S. market representing $1.9 billion. Although the exact etiology of primary open angle glaucoma remains poorly understood, and may be variable across patient subsets, it is generally accepted that the observed increase in IOP correlates with progressive vision loss1. Current treatments for POAG primarily consist of eyedrops that can be grouped into three main categories: prostaglandin analogues, carbonic anhydrous inhibitors, and alpha-2 agonists. While these approaches usually provide partial improvement, they often result in side effects such as redness and stinging and require multiple daily applications; all of which diminish patient compliance. Tryptamines, including DMT-analogues are thought to work in a completely distinct way to lower IOP and as such potentially embody a new class of glaucoma medications that may be used alone, or in combination with already approved medications. The Company's streamlined focus on two highly promising, undisclosed tryptamines as a potential therapeutic solution in treating glaucoma represents a potential paradigm shift.

Modulating the serotonin receptor pathway to improve glaucoma outcomes

Key regions of the eye that regulate fluid dynamics, including maintenance of healthy IOP, are known to be richly decorated with various serotonin receptor family members. Previous research has highlighted the role of serotonin receptor signaling in the regulation of IOP2-5. Tryptamines, often hallucinogenic above certain threshold concentrations, constitute a large collection of molecules that selectively act on multiple different serotonin receptors including 5-HT1A and 5-HT2A. Topical application of several different tryptamines have shown early promise in preclinical models of elevated IOP, however formulation, delivery, the potential for undesirable hallucinogenic side effects, and the controlled substances act of 1970 have all contributed to a lack of development of tryptamines to treat this serious threat to vision.

About Terasaki Institute for Biomedical Innovation

The Terasaki Institute for Biomedical Innovation is a biotechnology institute which develops medical devices and cutting-edge protocols for a variety of diagnostic, monitoring and treatment applications. Their research platforms include work in biomaterials, cellular and tissue engineering, wearable biosensors and organs-on-a-chip, with specific expertise in novel polymer development.

About PharmaDrug Inc.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH ("Pharmadrug Production"), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug owns 100% Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms, and psilocybin mushrooms where federally legal, as natural based medicines.

For further information, please contact:

Daniel Cohen, Chairman and CEO dcohen@pharmadrug.co(647) 202-1824

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains "forward-looking information" within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. In particular, this press release contains forward-looking information in relation to: future in vivo efficacy testing in an accepted model of primary open angle glaucoma (POAG), the ability to complete the required studies and obtain regulatory approval, and the impact the Company's potential products will have on treating glaucoma. This forward-looking information reflects the Company's current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to the ability of the Company to successfully execute on its plans for the Company and its affiliated entities; the ability to obtain required regulatory approvals and the Company's continued response and ability to navigate the COVID-19 pandemic being consistent with, or better than, its ability and response to date.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals; risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions; and a deterioration of financial markets that could limit the Company's ability to obtain external financing.

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at http://www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

References:

Weinreb RN, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. doi: 10.1038/nrdp.2016.67. PMID: 27654570.

May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther. 2003 Jul;306(1):301-9. doi: 10.1124/jpet.103.049528. Epub 2003 Apr 3. PMID: 12676887.

Sharif NA. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. doi: 10.2174/138945010791591278. PMID: 20426763.

Najam A Sharif & Jesse A May (2011) Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT2 receptor agonists, Expert Review of Ophthalmology, 6:1, 105-120, DOI: 10.1586/eop.10.69

Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J Ocul Pharmacol Ther. 2007 Feb;23(1):1-13. doi: 10.1089/jop.2006.0093. PMID: 17341144.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122498

See the original post:
Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for...

Read More...

Best Eye Hospital in North-East Region : The Retina Centre, Guwahati – APN News

Sunday, May 8th, 2022

There has been a significant increase in eye diseases in the people of India for the last several years. The doctors of The Retina Centre, Guwahati told the media on this subject that there can be many reasons for eye problems, including pollution, excessive use of mobile Use, stress, use of tobacco and other intoxicants, disordered eating, eye injury etc. are prominent.

Our eyes are precious but our slightest carelessness towards the eyes can also make us a victim of blindness. Many people ignore the initial symptoms of eye problems and gradually these problems take a serious form in them. That is why it is necessary not to ignore eye diseases and consult a doctor immediately as soon as the initial symptoms appear.

The officials of The Retina Center told the media that this institute of theirs has become the best eye hospital in the entire North-East region. Officials said that not only are the best doctors working here, but advanced medical procedures are available at affordable rates through modern resources.

The following eye diseases are treated by The Retina Centre.

Retinal Diseases:

The retina is the tissue that lines the inside of the eye and is sensitive to light. It sends visual messages to the brain through the optic nerve. Retinal diseases can affect any part of the retina and vary widely, but most of them cause visual symptoms. In the hospital, scleral buckling, vitrectomy (without suture), pneumorretinopexy, anti VEGF treatment, laser treatment etc. are done.

Corneal Disorders:

The cornea is a clear layer in front of the iris and the pupil. It protects the iris and lens and helps to focus light on the retina. Corneal disease is a serious condition that can lead to deformity, scarring and eventually blindness. Keratoplasty andTreatment services like Keratoprosthesis are available.

cataracts :

Cataract is a serious disease of the eyes. Cataracts usually occur with ageing or develop for no apparent reason. Most cataracts can be removed and replaced with artificial lenses. For this, facilities like Phacoemulsification with IOL implantation are available in the hospital.

Glaucoma:

Glaucoma is progressive optic nerve damage that leads to irreversible loss of vision. Glaucoma can occur at any age but it is 6 times more common in people over the age of 60. The Retina Center provides treatment for this like Filtration Surgery, Valve Implantation.

eye surgery:

Eye surgery Early diagnosis of eye conditions can help prevent further deterioration in eye health, improve vision and cure most eye diseases. Treatment includes simple medication, non-invasive and invasive procedures may be involved. For this, facilities like Retina Surgery, Glaucoma, Cataract Surgery, Neuro Opthalmology, Squint, Oculoplasty, Pediatric, Opthalmology are available in the hospital.

Hospital Address and Contact:

5th and 6th Floor, Subham Bijay Crescent,

6th Mile, Rukmini Gaon,

GS Road, Guwahati-781022, Assam

http://www.theretinacentre.com

Go here to read the rest:
Best Eye Hospital in North-East Region : The Retina Centre, Guwahati - APN News

Read More...

Bucks hospitals rally to deliver urgent supplies to Ukraine – Bucks Herald

Sunday, May 8th, 2022

Led by Ukrainian doctor practicing in the UK, Dr Sergey Tadtayev a consultant urologist surgeon, staff at Chiltern in Great Missenden, and Shelburne Hospital have managed to deliver supplies to the war-torn country.

Circle Health Group, Sergeys hospital operator, has also played a key role in getting the urgent supplies to Ukraine.

In response to direct requests from Ukrainian doctors, the hospitals have worked with the Ukrainian doctors union (Ukraine Medical Association) and the British Red Cross to identify needs in war-hit hospitals.

Also, Sergey has galvanised his Circle colleagues to gather 10-truck loads including 200 pallets of vital kit and medical supplies from across the groups national network of 53 hospitals.

Sergey said: My heart breaks for my fellow doctors back home who are fighting heroically to care for the sick and wounded even as the bombs continue to fall.

"Hospitals are struggling to get basic supplies because transport and manufacturing have been so badly disrupted, so I knew I had to do something to help.

Moving 100+ tonnes of medical supplies between hospitals separated by thousands of miles and several borders has been an incredible team effort, and I have been overwhelmed by the generosity of my colleagues at Circle Health Group.

"They are moving heaven and earth to get help to those who really need it on the frontline, and I am humbled by the solidarity and support for my homeland.

Ventilators, crutches, walking frames, respiratory masks, scrubs, bandages, wound kits, operating tables and other medical supplies have been stock-piled from Circle hospitals across the country and delivered directly to the doors of five hospitals covering North, South, East and West Ukraine.

Upon receipt of the urgent supplies, the hospitals distribute a portion to local community hospitals.

A team of volunteers from the UK, Poland and Ukraine have made the journey on a weekly basis since 15 March to deliver urgent supplies, navigating their way through war-torn regions and areas of conflict to reach the hospitals in Kyiv, Kharkiv, Mykolaiv, Odessa and Lviv.

Circle Health Group has committed to continue the weekly delivery programme for as long as the supplies are required.

The latest delivery, which departed the UK on Wednesday 13 April and arrived at a Kharkiv hospitals on Easter Sunday (17 April), contained 185,500 of medical equipment loaded on 35 pallets, including five ventilators, an operating table, patient monitors, suction tubing and chest drainage sets and sterile gowns.

One of the hospitals opthalmic consultants, Mandeep Bindra, and Healthcare Assistant Adinda Ecott, co-ordinated the collection of supplies ranging from blankets to hot water bottles and baby food. Mandeep personally drove the supplies to two collection centres, one in Hounslow and one at the Olympic Lodge in Aylesbury.

The collected items will then be transported by lorry to the Polish border where they will be given to Ukrainian families.

Overall, 1.4 million worth of supplies have been sent from Circle Health Group hospitals.

Paolo Pieri, CEO of Circle Health Group, said: Were so grateful to the hundreds of people across the country who have contributed to this effort, from staff to partners and suppliers, and the brave drivers who have put themselves at considerable personal risk."

Read the rest here:
Bucks hospitals rally to deliver urgent supplies to Ukraine - Bucks Herald

Read More...

LianBio (NASDAQ:LIAN) Expected to Post Earnings of -$0.26 Per Share – Defense World

Tuesday, April 26th, 2022

Equities analysts expect LianBio (NASDAQ:LIAN Get Rating) to announce earnings per share (EPS) of ($0.26) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for LianBios earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.31). The firm is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that LianBio will report full-year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.07). For the next year, analysts expect that the business will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.20) to ($1.44). Zacks Investment Researchs EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for LianBio.

LianBio (NASDAQ:LIAN Get Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts consensus estimates of ($0.72) by $0.44.

Several institutional investors have recently modified their holdings of LIAN. Victory Capital Management Inc. acquired a new stake in LianBio during the 4th quarter worth $1,069,000. Bank of America Corp DE acquired a new stake in LianBio during the 4th quarter worth $519,000. Alps Advisors Inc. acquired a new stake in LianBio during the 4th quarter worth $750,000. Element Capital Management LLC acquired a new stake in LianBio during the 4th quarter worth $124,000. Finally, TD Asset Management Inc. acquired a new position in shares of LianBio in the 4th quarter valued at $954,000. 62.99% of the stock is owned by institutional investors and hedge funds.

Shares of LianBio stock traded down $0.26 during midday trading on Thursday, reaching $4.91. The company had a trading volume of 435,320 shares, compared to its average volume of 411,834. The companys fifty day moving average is $4.19. LianBio has a 1-year low of $2.61 and a 1-year high of $16.37.

About LianBio (Get Rating)

Lianbio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor IO combinations; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric and other cancers; BBP-398 for solid tumors; Omilancor for ulcerative and Crohn's disease; NH-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

Recommended Stories

Get a free copy of the Zacks research report on LianBio (LIAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.

See more here:
LianBio (NASDAQ:LIAN) Expected to Post Earnings of -$0.26 Per Share - Defense World

Read More...

PGIMER to review operations as OPD footfall rises – Hindustan Times

Tuesday, October 5th, 2021

With the number of patients getting physically examined at outpatient departments (OPDs) of Post Graduate Institute of Medical Education and Research (PGIMER) rising by 67% over a week, the institute will call a review meeting in a week to decide upon the operations.

The PGIMER had resumed the walk-in facility for physical consultation at its OPDs on September 27. Since then, in the six working days, 32,913 patients were physically examined while 8,540 people were given consultation on telephones. The OPDs were closed on Saturday (Gandhi Jayanti) and Sunday.

On Monday, 6,579 patients got physical consultation at the hospitals New OPD department, as compared to 3,942 last Monday. Before the resumption of the walk-in facility, nearly 3,000 patients were visiting various OPDs daily, after prior appointments through tele-consultation or official website.

Keeping in view the possibility of a third wave, the institute authorities believe that capping the number of patients for physical examination is important. The institute is providing tele-consultation only between 8 am to 9 am, to scale up physical consultation.

The number of patients coming to the institute is more than expected. Since Covid-19 cases in Chandigarh and neighbouring states are fluctuating daily, crowding at one place can spread the infection. A cap of numbers and resuming OPDs in a phased manner is a must, said a PGIMER official, who did not wish to be named.

Dr Jagat Ram, director, PGIMER, said that on an average, 6,000 patients are visiting the institute daily, and each patient has two or three attendants with them. The total footfall is more than 18,000 daily.

At present, we are trying to manage the crowd and are accessing problems being faced by patients. In a week, we will call a review meeting with heads of each department and will decide upon further action. Guidelines on OPD operations will be reviewed, he said.

Before the contagion, over 10,000 patients visited PGIMERs OPDs daily. Since the suspension of walk-in consultation and online appointments in March last year, the institute had been providing OPD services through tele-consultation. From June 21 this year, physical consultations resumed, but only after prior appointment through tele-consultation.

On September 6, the institute also restarted an online appointment facility, but with a cap of 30 patients per department to ensure adherence to Covid protocols. Later, the limit was increased to 50 patients, with 100 allowed at three major departments opthalmology (eye), hepatology (liver) and internal medicine.

Now, patients can simply walk into the institutes New OPD between 9.15am and 11am and get registered.

More:
PGIMER to review operations as OPD footfall rises - Hindustan Times

Read More...

Coronavirus Impact Editon of Opthalmology Drugs and Devices Coronavirus Impact Editon of Insights with COVID-19 Impact Analysis by 2020Merck (US),…

Wednesday, July 21st, 2021

Newly Report on Opthalmology Drugs and Devices Market 2021, Growth, Share Types and Key Players | Merck (US), Pfizer (US), Roche Holdings (Switzerland), Santen Pharmaceutical(Japan), Abbott Medical Optics (US), Alcon (Switzerland), Bausch& Lomb (US), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson& Johnson (US), Nidek(Japan), Topcon Corporation (Japan)

COVID-19 Impact on Global Opthalmology Drugs and Devices Market Research Report 2021-2028

The global Opthalmology Drugs and Devices market report examines the market position and viewpoint of the market worldwide, from various angles, such as from the key players point, geological regions, types of product and application. This Opthalmology Drugs and Devices report highlights the key driving factors, constraint, opportunities, challenges in the competitive market. It also offers thorough Opthalmology Drugs and Devices analysis on the market stake, classification, and revenue projection. The Opthalmology Drugs and Devices market report delivers market status from the readers point of view, providing certain market stats and business intuitions. The global Opthalmology Drugs and Devices industry includes historical and futuristic data related to the industry. It also includes company information of each market player, capacity, profit, Opthalmology Drugs and Devices product information, price, and so on.

The latest Opthalmology Drugs and Devices market report published by Cognitive Market Research offers a competency-based analysis and global market estimate, developed using evaluable methods, to provide a clear view of current and expected growth patterns. The report also contains market analysis by geographic location across the globe as well as major markets.

The key manufacturers covered in this report areMerck (US), Pfizer (US), Roche Holdings (Switzerland), Santen Pharmaceutical(Japan), Abbott Medical Optics (US), Alcon (Switzerland), Bausch& Lomb (US), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson& Johnson (US), Nidek(Japan), Topcon Corporation (Japan)

The product type segment discusses the different kinds of products made available by the Global Opthalmology Drugs and Devices market:Device, Drug

The product application segment examines the different end-users operational in the Global {Opthalmology Drugs and Devices} market:Hosptial, Clinic, Others

Get a sample copy of the report @ https://cognitivemarketresearch.com/medical-devicesconsumables/opthalmology-drugs-and-devices-market-report#download_report

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research MethodologyThe data that has been collected is from a multitude of different services that include both primary and secondary sources. The data also includes a list of the different factors that affect the Opthalmology Drugs and Devices market either positively or negatively. The data has been subjected to a SWOT analysis that can be used to accurately predict the various parameters that are used to measure a companys growth. The strengths along with various weaknesses faced by a company are included in the report along with a comprehensive analysis of the different threats and opportunities that can be exploited.

Get Enquiry on this Report @ https://cognitivemarketresearch.com/medical-devicesconsumables/opthalmology-drugs-and-devices-market-report#download_report

To understand the global Opthalmology Drugs and Devices market dynamics, the market is analyzed across major global regions and countries. Cognitive Market Research provides customized specific regional and country-wise analysis of the key geographical regions as follows:North AmericaEuropeAsia Pacific CounterMiddle East & AfricaLatin AmericaAmerica Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

About Author:Cognitive Market Research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. This helps in understanding the market players and the growth forecast of the products and so the company. This is where market research companies come into the picture. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Contact Us:Cognitive Market ResearchContact Person: Nicolas Shaw, Sales ManagerEmail: [emailprotected]Phone: +1 312-376-8303 | (+44) 20-8144-9523

https://murphyshockeylaw.net/

Read the rest here:
Coronavirus Impact Editon of Opthalmology Drugs and Devices Coronavirus Impact Editon of Insights with COVID-19 Impact Analysis by 2020Merck (US),...

Read More...

Page 11234..10..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick